In contrast, the American Society of Clinical Oncology guidelines state that the clinician should not use the 21-gene RS to guide therapy in node positive ER+/HER2− breast cancer.23 While prospective clinical trials are ongoing to answer this question, these disparate recommendations may lead to confusion among patients and providers and thus impact reimbursement by payers.22 Here, ESR1 is linked to breast carcinoma.